Banque Cantonale Vaudoise Boosts Holdings in Exact Sciences Co. (NASDAQ:EXAS)

Banque Cantonale Vaudoise boosted its position in shares of Exact Sciences Co. (NASDAQ:EXAS) by 35.6% during the 1st quarter, according to its most recent 13F filing with the SEC. The fund owned 6,841 shares of the medical research company’s stock after purchasing an additional 1,795 shares during the quarter. Banque Cantonale Vaudoise’s holdings in Exact Sciences were worth $472,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. Wolff Wiese Magana LLC lifted its stake in shares of Exact Sciences by 459.5% in the fourth quarter. Wolff Wiese Magana LLC now owns 414 shares of the medical research company’s stock worth $31,000 after buying an additional 340 shares in the last quarter. Able Wealth Management LLC purchased a new stake in Exact Sciences during the 4th quarter valued at $45,000. Valley National Advisers Inc. increased its holdings in shares of Exact Sciences by 29.5% in the 3rd quarter. Valley National Advisers Inc. now owns 773 shares of the medical research company’s stock worth $53,000 after purchasing an additional 176 shares in the last quarter. National Bank of Canada FI increased its holdings in shares of Exact Sciences by 30.9% in the 4th quarter. National Bank of Canada FI now owns 848 shares of the medical research company’s stock worth $63,000 after purchasing an additional 200 shares in the last quarter. Finally, Quest Partners LLC purchased a new position in shares of Exact Sciences in the fourth quarter worth $66,000. 88.82% of the stock is currently owned by institutional investors.

Exact Sciences Trading Up 1.9 %

NASDAQ EXAS opened at $44.85 on Friday. Exact Sciences Co. has a 52 week low of $41.08 and a 52 week high of $100.77. The company has a quick ratio of 1.45, a current ratio of 1.64 and a debt-to-equity ratio of 0.66. The stock’s 50-day moving average price is $52.46 and its 200-day moving average price is $60.99.

Exact Sciences (NASDAQ:EXAS) last released its earnings results on Wednesday, May 8th. The medical research company reported ($0.50) EPS for the quarter, hitting analysts’ consensus estimates of ($0.50). Exact Sciences had a negative net margin of 9.48% and a negative return on equity of 7.12%. The company had revenue of $637.52 million for the quarter, compared to analysts’ expectations of $624.95 million. Equities research analysts predict that Exact Sciences Co. will post -1.15 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on the company. BTIG Research reduced their price objective on Exact Sciences from $85.00 to $80.00 and set a “buy” rating for the company in a report on Thursday, May 9th. Citigroup decreased their price objective on shares of Exact Sciences from $100.00 to $80.00 and set a “buy” rating for the company in a report on Thursday, May 9th. Canaccord Genuity Group dropped their target price on shares of Exact Sciences from $90.00 to $85.00 and set a “buy” rating on the stock in a report on Thursday, May 9th. Jefferies Financial Group began coverage on shares of Exact Sciences in a research note on Monday, June 3rd. They set a “buy” rating and a $75.00 target price for the company. Finally, TheStreet downgraded Exact Sciences from a “c-” rating to a “d+” rating in a research note on Monday, February 26th. Two equities research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company’s stock. According to MarketBeat, Exact Sciences currently has an average rating of “Moderate Buy” and an average price target of $90.00.

Insider Buying and Selling

In other Exact Sciences news, CEO Kevin T. Conroy sold 1,155 shares of the firm’s stock in a transaction dated Wednesday, May 1st. The stock was sold at an average price of $60.15, for a total transaction of $69,473.25. Following the sale, the chief executive officer now directly owns 1,156,191 shares of the company’s stock, valued at $69,544,888.65. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. In other Exact Sciences news, CEO Kevin T. Conroy sold 1,155 shares of the company’s stock in a transaction that occurred on Wednesday, May 1st. The stock was sold at an average price of $60.15, for a total value of $69,473.25. Following the completion of the transaction, the chief executive officer now directly owns 1,156,191 shares in the company, valued at approximately $69,544,888.65. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Sarah Condella sold 2,000 shares of the stock in a transaction that occurred on Monday, April 1st. The shares were sold at an average price of $70.00, for a total transaction of $140,000.00. Following the sale, the executive vice president now directly owns 71,787 shares of the company’s stock, valued at $5,025,090. The disclosure for this sale can be found here. In the last quarter, insiders sold 5,498 shares of company stock valued at $370,105. Company insiders own 1.36% of the company’s stock.

Exact Sciences Profile

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.